Clinical trials: Neoplasm Recurrence, Local
Portal Vein Thrombosis, Local Cause
Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause.
In case of acute portal vein thrombosis (PVT) prothrombotic factors are identified in about 60% of cases, while a local condition is present in 30% of cases.
- Trial name
- LOCAPORT (NCT05360641)
- Where
- France
- Volunteers
- 154 people
- Sponsor
- University Hospital, Caen
Local Recurrence of Malignant Tumor of Breast
Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients
Breast-conserving surgery (BCS) is the traditional surgical treatment for early-stage breast cancer patients. There are evidences indicating that oncoplastic-BCS (displacement technique) could improve cosmetic outcomes and/or…
- Trial name
- NCT02376413
- Testing
- Breast surgery, Chemotherapy or endocrine therapy or Trastuzumab therapy, Radiation therapy
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Osteosarcoma, Resection Margins
B7-H3 NIR Imaging for Osteosarcoma Surgery
Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and…
- Conditions
- Osteosarcoma, Resection Margins, B7-H3 Probe, Local Recurrence
- Trial name
- ROLN-B7-H3 (NCT06778603)
- Testing
- a targeted probe B7H3-IRDye800CW
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University People's Hospital
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Colorectal Cancer, Liver Metastases
COLLISION RELAPSE Trial
The primary objective is to demonstrate superiority of neoadjuvant systemic therapy followed by repeat local treatment as compared to upfront repeat local treatment in patients with at least one locally treatable recurrent CRLM…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Chemotherapy Effect
- Trial name
- NCT05861505
- Testing
- Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B), Repeat local treatment
- Where
- Netherlands
- Volunteers
- 360 people
- Sponsor
- Amsterdam UMC, location VUmc
Breast Cancer
TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry
Quality Control Registry for IORT used as an anticipiated boost with 20 Gy at the applicator surface followed by EBRT
- Trial name
- TARGIT_BQR (NCT01440010)
- Testing
- IORT with 20 Gy
- Where
- Germany
- Volunteers
- 1,133 people
- Sponsor
- Universitätsmedizin Mannheim
Primary Inoperable Thymoma, Local Recurrent Thymoma
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
This is a monocenter, single-arm, open label phase II trial evaluating the effect of SOM230 LAR in adult patients with inoperable primary thymoma and thymoma metastasis (Masaoka II-IVa).
- Trial name
- NCT02021942
- Testing
- SOM230 LAR
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Prof. Dr. Berthold Schalke
Colorectal Cancer, Recurrence, Local Neoplasm
Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars
Nowadays endoscopic mucosal resection (EMR) is the gold standard for the removal of large laterally spreading and sessile colorectal lesions ≥ 20 mm.
- Trial name
- NCT04239365
- Testing
- WLE followed by NBI or NBI followed by WLE (crossover design)
- Where
- Portugal
- Volunteers
- 210 people
- Sponsor
- Portuguese Oncology Institute, Coimbra
Local Recurrence of Malignant Tumor of Soft Tissue
Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas
The randomized, controlled trial is aiming at comparing local control rate between two surgical resections, barrier resection and local wide resection with 1cm or equivalent normal tissues.
- Trial name
- NCT02120768
- Testing
- barrier resection/1cm resection
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Breast Cancer
DianaWeb: Before and After Study Online Based Participatory Research on Breast Cancer Women
DianaWeb is a community-based participatory research (CBPR) offered to Italian breast cancer patients. The aim of the study is the evaluation of effectiveness of a lifestyle and nutrition intervention to improve the prognosis.
- Trial name
- DianaWeb (NCT05057598)
- Testing
- Community-based participatory research on diet and lifestyle
- Where
- Italy
- Volunteers
- 50,000 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Colorectal Cancer (CRC)
A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study)
With high incidence and mortality rate, the effective therapeutic options of colorectal cancer remain limited. Up to 50% of patients with colorectal cancer will develop metastatic disease.
- Trial name
- PROBE (NCT07685236)
- Volunteers
- 586 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer
Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients
The primary curative treatment of lung cancer patients is surgery, chemotherapy and/or radiation therapy (either or all depending on the extent of disease).
- Trial name
- NCT01757158
- Testing
- Cs-131 brachytherapy seeds
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Trial name
- NCT00427349
- Testing
- AMG 706, octreotide
- Where
- 112 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt.
- Conditions
- Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma
- Trial name
- NCT04185038
- Testing
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Seattle Children's Hospital